This study focuses on adults with advanced melanoma (a type of skin cancer) that has spread or cannot be surgically removed. The purpose of the study is to determine whether an experimental drug called IMC-F106C, in combination with a standard therapy (nivolumab), works better than the standard therapy (nivolumab alone or in combination with relatlimab) at stopping tumors from growing. Researchers also want to better understand the safety of IMC-F106C in combination with nivolumab and learn whether a lower or higher dose of IMC-F106C in combination with this standard therapy works better and/or is safer. In addition, the study will evaluate how well participants feel after receiving the study drug or standard therapy. IMC-F106C may help T cells (part of the body’s immune system) stick to and attack cancer cells. Nivolumab is approved by the U.S. Food and Drug Administration (FDA) for various conditions, but the combination of IMC-F106C and nivolumab in this study is investigational.